Recombinant pseudocowpoxvirus
AssigneeTransgene S.A.
InventorsKarola Rittner, Christelle Remy, Christine Thioudellet
Life of this patent
Estimating the term…
Abstract
The present invention is in the field of viral immunotherapy. The invention provides new pseudocowpox (PCPV) viruses, in particular recombinant PCPV, composition thereof as well as their therapeutic use for preventing or treating diseases, and, notably, proliferative diseases like cancers and restenosis and infectious diseases such as chronic ones. The present invention also provides methods for generating and amplifying such a PCPV and a method for eliciting or stimulating and/or re-orienting an immune response using such a PCPV. More specifically, the invention provides an alternative to the existing poxvirus vectors such as MVA (Modified Virus Ankara) and may be largely used for the therapeutic vaccination.
Claims10
A vaccine composition comprising a therapeutically effective amount of a pseudocowpoxvirus (PCPV) and a pharmaceutically acceptable vehicle;
- wherein said PCPV comprises at least one foreign nucleic acid inserted in its genome;
- wherein said at least one foreign nucleic acid encodes a cancer antigen;
- and wherein the insertion site is selected from the group consisting of a non-essential viral gene, an intergenic region, a portion of the PCPV genome which does not encode gene products, and a duplicated locus.
Dependencies are inferred from the claim text.